Innovative Digital Biomarkers Altoida has developed a proprietary platform that leverages augmented reality and machine learning to objectively assess neurological health, particularly for early detection of Alzheimer’s Disease. This technological edge offers opportunities to collaborate with healthcare providers and pharmaceutical companies seeking advanced diagnostic tools for neurodegenerative conditions.

Strong Scientific Foundation With over 20 years of scientific research underpinning its technology and peer-reviewed publications including in Nature Digital Medicine, Altoida’s platforms are credible and validated, making them attractive for partnerships with research institutions and healthcare organizations aiming to integrate evidence-based solutions into patient care.

Recognition & Industry Leadership Altoida received the Gold Award for Best Use of Artificial Intelligence and has been featured in recent studies and partnerships with pharmaceutical companies, such as Esai. These accolades position Altoida as a leading innovator in AI-powered neurodiagnostics, opening doors for strategic collaborations and funding opportunities.

Strategic Growth Initiatives With recent leadership changes and plans for FDA clearance through upcoming clinical studies, Altoida is scaling its commercial operations. There is potential to engage with their expanding sales and clinical teams to provide complementary solutions that enhance early diagnosis and monitoring of cognitive decline.

Funding and Market Opportunity Having secured $14M in funding and operating in a niche market with a revenue range of $1M to $10M, Altoida presents an attractive opportunity for investors and partners looking to enter or expand within the health technology and digital biomarker space targeting neurodegenerative diseases.